TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03514745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope
Description: Endobronchial intubation is performed using the GlideScope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lighted stylet
Description: Endobronchial intubation is performed using a lighted stylet.
Study: NCT04999683

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ITIS diet
Description: anti-inflammatory diet for 14 days
Study: NCT02046057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PNB of SLN
Description: Percutaneous biopsy of sentinel node
Study: NCT00650156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 80 mg single sc dose
Study: NCT03513354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soil group
Description: Exercises in soil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soil group
Description: Exercises in soil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pool group
Description: Exercises in pool.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pool group
Description: Exercises in pool.
Study: NCT03674710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard suction, slow-pull, wet suction
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard suction, wet suction, slow-pull
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow-pull, standard suction, wet suction
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow-pull, wet suction, standard suction
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.
Study: NCT02960035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg etanercept
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
Study: NCT01743950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 10mg/kg every 2weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PRDR
Description: Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
Study: NCT02960035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02648282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX Pancreatic Cancer Vaccine
Description: 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of 8 doses. In the extended treatment phase, eligible patients may receive 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells administered one day after CY every 6 months for an additional 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg as a 30 minute IV infusion every 21 days for an additional 9 doses.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX Pancreas Vaccine).
Study: NCT00582686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF of Calcaneus without bone grafting
Description: The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
Study: NCT03214094

Intervention type: DRUG
Intervention: Vonoprazan
Description: Vonoprazan tablets
Study: NCT04061538

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: zinc 20mg tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic zinc 20mg tablet
Study: NCT02711111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face mask
Description: to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic bone anchor
Description: to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
Study: NCT02527343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volanesorsen
Description: 300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volanesorsen
Description: 300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Volanesorsen-matching placebo administered SC injection.
Study: NCT01029652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide 40 mg
Description: Triamcinolone acetonide 40 mg was supplied as a suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to canakinumab
Description: Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to triamcinolone acetonide
Description: Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
Study: NCT01419457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1200 mg BID for Day 1 + 800 mg BID for Day 2-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1200 mg BID for Day 1 + 800 mg BID for Day 2-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1200 mg BID for Day 1 + 800 mg BID for Day 2-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 800 mg BID for Day 1 + 400 mg BID for Day 2-3
Study: NCT03674710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet suction, standard suction, slow-pull
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet suction, slow-pull, standard suction
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.
Study: NCT02959775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg dose hepatitis B vaccine
Description: three-dose, 60 µg per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: three-dose, 20 µg per dose
Study: NCT02067780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: One tablet per day for 7days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: One tablet per day for 7days.
Study: NCT04996602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0 GBq of 177Lu-EB-PSMA
Description: Patients were intravenous administrated with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA every 8 weeks (±1 week) for a maximum of 3 cycles.
Study: NCT01268930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar electrocautery for ovarian hemostasis
Description: after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.
Study: NCT01743950

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PRDR
Description: Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PRDR
Description: Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PRDR
Description: Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
Study: NCT03202381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~* Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~* Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression.
Study: NCT03706118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: At month 0, 12, 24 and 36 participants will be examined by quantitative magnetic resonance imaging of brain, cervical and part of thoracic spine.
Study: NCT03684486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation by effort
Study: NCT01552564

Intervention type: PROCEDURE
Intervention: Index of microvascular resistance

Intervention type: OTHER
Intervention: Cardiac magnetic resonance

Intervention type: OTHER
Intervention: Blood markers
Study: NCT01005342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oat bran
Description: 82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spray-dried oat drink
Description: 62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye bran
Description: 31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar beet fiber
Description: 19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
Study: NCT01268930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemostatic matrix (FloSeal)
Description: after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.
Study: NCT03689374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine U100
Description: Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine U100
Description: Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
Study: NCT02254967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: oral tablets administered in an extended pulsed regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: oral capsule
Study: NCT01680159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Study: NCT02780453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound dressing
Study: NCT01703507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT01005342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixture of fiber
Description: 38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No fiber was added to control meal (250 g black-currant beverage)
Study: NCT02805426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study: NCT00000431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDGF-B/Ad5
Description: This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
Study: NCT03764072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Capsules for oral administration.
Study: NCT01703507

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiation Therapy (WBRT)
Description: Undergo WBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Undergo SRS
Study: NCT03764072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Capsules for oral administration.
Study: NCT02949323

Intervention type: OTHER
Intervention: urinary stone
Description: patients of group one have urinary stones
Study: NCT00909727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150-mg tablet given orally q12h for up to 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet given orally q12h for up to 48 weeks
Study: NCT02450565

Intervention type: OTHER
Intervention: Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Study: NCT02748226

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: endovascular treatment

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: endovascular treatment
Study: NCT00760877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Supplied in 200 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Supplied in 100 mg and 400 mg capsules
Study: NCT03950596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute resistant load exercises
Description: Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute resistant load exercises
Description: Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Background Questionnaire
Description: Background questionnaire will be filled out by participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Background Questionnaire
Description: Background questionnaire will be filled out by participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Background Questionnaire
Description: Background questionnaire will be filled out by participants
Study: NCT00942461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic colectomy
Description: Laparoscopic colectomy. Epidural anaesthesia used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open colectomy
Description: Open colectomy. Epidural anaesthesia used
Study: NCT00492206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
Study: NCT02823899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HL-OCV
Description: Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
Study: NCT03764072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration.
Study: NCT03950596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Questionnaire
Description: Pain questionnaire regarding pain in the knee during previous 3 months
Study: NCT04012684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
Study: NCT02355028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHA510 ophthalmic suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LHA510 vehicle
Description: Inactive ingredients used as a placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab ophthalmic solution
Description: For intravitreal (IVT) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranibizumab ophthalmic solution
Description: For intravitreal (IVT) injection
Study: NCT00724581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
Study: NCT01298505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764 2.5mg plus fexofenadine 60mg
Description: PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
Study: NCT05635435

Intervention type: OTHER
Intervention: Detection of Immune and Inflammatory Indices in Peripheral Blood
Description: We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.
Study: NCT01298505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764 5mg plus fexofenadine 60mg
Description: PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo given twice daily for 7 days